Lactulose and Peginterferon drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lactulose (lactulose) and Peginterferon (peginterferon alfa-2a; ribavirin). Common drug interactions include decreased appetite among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Lactulose and Peginterferon. It is created by eHealthMe based on reports of 47 people who take the same drugs from the FDA, and is updated regularly.

What is Lactulose?

Lactulose has active ingredients of lactulose. It is often used in constipation. eHealthMe is studying from 46,960 Lactulose users. Check the latest studies of Lactulose.

What is Peginterferon?

Peginterferon has active ingredients of peginterferon alfa-2a; ribavirin. It is often used in hepatitis c. eHealthMe is studying from 13,778 Peginterferon users. Check the latest studies of Peginterferon.

On Jul, 31, 2026

47 people who take Lactulose and Peginterferon together, and have interactions are studied.

Lactulose and Peginterferon drug interactions.

What are the common drug interactions of Lactulose and Peginterferon, by gender? *:

female:

Decreased appetite
Device related infection
Diarrhoea
Diffuse large b-cell lymphoma (cancer of b cells, a type of white blood cell)
Dry mouth
Dyspnoea (difficult or laboured respiration)
Ecchymosis (a discoloration of the skin resulting from bleeding underneath)
Epistaxis (bleed from the nose)
Erythema (redness of the skin)
Fatigue (feeling of tiredness)

male:

Anaemia (lack of blood)
Thrombocytopenia (decrease of platelets in blood)
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Hepatorenal syndrome (renal failure in patients with advanced chronic liver disease)
Oedema peripheral (superficial swelling)
Oral candidiasis (fungal infection of mouth)
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
Acute hepatic failure
Ascites (accumulation of fluid in the abdominal cavity)

What are the common drug interactions of Lactulose and Peginterferon, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Feeding tube complication
Food intolerance (inability to have food)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)

30-39:

n/a

40-49:

Fatigue (feeling of tiredness)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
Hyperuricaemia (level of uric acid in the blood that is abnormally high)
Hypophagia (reduced food intake)
Injection site erythema (redness at injection site)
Ischaemic gastritis (inflammation of the lining of the stomach due to inadequate supply of blood)
Multi-organ failure (multisystem organ failure)
Nasopharyngitis (inflammation of the nasopharynx)
Oral pain

50-59:

Abdominal pain
Anaemia (lack of blood)
Blood bilirubin increased
Chronic hepatic failure (long lasting liver failure)
Diarrhoea
Hepatic cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue)
Thrombocytopenia (decrease of platelets in blood)
Loss of consciousness
Bone marrow failure
Dehydration (dryness resulting from the removal of water)

60+:

Blood bilirubin increased
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Anaemia (lack of blood)
Neutropenia (an abnormally low number of neutrophils)
Thrombocytopenia (decrease of platelets in blood)
Asthma
Head injury
Headache (pain in head)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Influenza

What are the existing conditions these people have? *

High Blood Pressure: 6 people, 12.77%
Diabetes: 6 people, 12.77%
Pain: 4 people, 8.51%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 4 people, 8.51%
Insomnia (sleeplessness): 3 people, 6.38%
Encephalopathy (functioning of the brain is affected by some agent or condition): 3 people, 6.38%

* Approximation only. Some reports may have incomplete information.

Do you take Lactulose and Peginterferon?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously